Peptide Receptor Radionuclide Therapy & Oncology
PRRT & Oncology
Neuroendocrine tumors (NETs) are rare neoplasms with differences in clinical presentation, course and prognosis. Most of the NETs express the somatostatine receptor, which can be utilized for imaging and therapy. Radiolabeled somatostatin analogs can be used for peptide receptor radionuclide therapy (PRRT) in NET patients. 177Lu- DOTATATE is one of the most used radiopeptides for PRRT with tumor response rates of 15–35%. However PRRT elicits side effects. The first (and main) part of this thesis will cover the short- and long-term side effect in NET patients treated with 177Lu-DOTATATE. Particular, toxicity profiles for the kidneys, bone marrow and spleen will be discussed. Prostate and breast cancer also have receptors that can be used for imaging and therapy. In the second part of this thesis we explore a novel Gastrin-releasing Peptide Receptor (GRPR) antagonist 68Ga-SB3 for imaging of prostate and breast cancer.
|Keywords||Peptide receptor radionuclide therapy, PRRT, neuroendocrine tumors, toxicity, bonemarrow, kidneys, spleen, GRPR, prostate cancer, breast cancer, imaging|
|Promotor||M. de Jong (Marion) , D.J. Kwekkeboom (Dirk Jan) , W.W. de Herder (Wouter) , M.W. Konijnenberg (Mark)|
|Publisher||Erasmus University Rotterdam|
Bergsma, H. (2017, September 26). Peptide Receptor Radionuclide Therapy & Oncology. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/101491